Want to join the conversation?
$REGN 2Q15 PR: Sanofi collaboration revenue was $195.1MM vs. $142.6MM in 2Q14. Bayer HealthCare collaboration revenue was $134.2MM vs. $97.3MM in 2Q14. Collaboration revenue grew primarily due to higher reimbursement of R&D expenses under antibody collaboration with Sanofi & an increase in net profit from commercialization of EYLEA outside the US.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?